Research progress in the treatment of B-cell acute lymphoblastic leukemia with blinatumomab
10.12354/j.issn.1000-8179.2023.20231028
- VernacularTitle:Blinatumomab治疗急性B淋巴细胞白血病的研究进展
- Author:
Xueyuan LI
1
,
2
;
Wenjing GUO
;
Sizhou FENG
Author Information
1. 天津医科大学(天津市 300070)
2. 细胞生态海河实验室
- Keywords:
blinatumomab;
acute lymphoblastic leukemia(ALL);
immunotherapy
- From:
Chinese Journal of Clinical Oncology
2023;50(22):1159-1163
- CountryChina
- Language:Chinese
-
Abstract:
B-cell acute lymphoblastic leukemia(ALL)is a hematological malignancy.Blinatumomab,as a therapeutic target,targeting CD19,has demonstrated notable efficacy as a safe bridge to allogeneic hematopoietic stem cell transplantation(allo-HSCT)in patients with re-lapsed/refractory acute lymphoblastic leukemia(R/R B-ALL).In the treatment of newly diagnosed ALL,blinatumomab,when combined with chemotherapy or other immunotherapies,reduces toxicity while ensuring efficacy.Similarly,combining blinatumomab with second-or third-generation tyrosine kinase inhibitors(TKIs)for the treatment of Philadelphia chromosome--positive(Ph+)ALL holds promise for eliminating the need for subsequent allo-HSCT in patients.Disease relapse and long-term survival of patients are closely related to minimal residual dis-ease(MRD)at the conclusion of treatment,and blinatumomab contributes to enhancing the MRD conversion rate in patients with ALL,thus improving the long-term prognosis.This article comprehensively reviews the clinical trials and current progress of blinatumomab in various B-ALL patient groups.
